asa glp-1 agonist guidelines medications safe to continue before surgery in patients with diabetes and obesity Impact of GLP-1 Receptor Agonists

Clinical trials have demonstrated varying efficacy across the class, with weight reductions ranging from approximately 5-8% with liraglutide 3 mg to 15% with semaglutide 2.4 mg and 10-22% with tirzepatide, depending on dose

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al

The global prevalence of 537 million affected in the age group of 2079 years in 2021 will rise to 783 million in 2045, with the lowest increase in incidence in Europe (13%) and the highest in the African countries south of the Sahara (134%) ( Obesity, defined as a body mass index above 30 kg/m 2 , is also increasingly prevalent worldwide and has become a challenge to the various healthcare systems and societies

(Injected GLP-1 drugs were in shortage until recently.) Pills can also be transported more readily

The study protocol was registered in the International Prospective Register of systematic reviews PROSPERO (CRD420251002447)